Get 40% Off
☕ Buy the dip? After losing 17%, Starbucks sees an estimated 20% upside. See the top Undervalued stocks!Unlock list

Vivek Ramaswamy's Parallels With Warren Buffett Run Deeper Than Wanting To Make Roivant The 'Berkshire Hathaway Of Drug Development'

Published 04/09/2023, 07:39
Updated 04/09/2023, 08:40
© Reuters.  Vivek Ramaswamy's Parallels With Warren Buffett Run Deeper Than Wanting To Make Roivant The 'Berkshire Hathaway Of Drug Development'

Benzinga - by Shanthi Rexaline, Benzinga Editor.

Republican presidential primary candidate Vivek Ramaswamy is making all the right noises and has appealed to people with his rank-outsider status and eloquence. A report delved into the similarities the presidential hopeful shares with billionaire investor Warren Buffett.

Investment Theme: Ramaswamy and Buffett differ in being on either side of the political spectrum. The “Oracle of Omaha” has previously advised former President Barack Obama and then went on to support Hillary Clinton when she ran for office in 2015. However, he has in the past few years disassociated himself from politics. His recent apolitical stance stems from the worry concerning the potential impact his statements or views may have on his employees and shareholders.

Both Ramaswamy and Buffett apparently have common grounds. They are interested in bargain buys and worry about the intersection of business and social issues, Business Insider said in a report.

Buffett is known for his “value investing” strategy of buying good companies at the right prices and holding them for long. This buy-and-hold strategy has served him well, as seen in the rise in the shares of Berkshire Hathaway, an investment-holding company he runs in the capacity of both chairman and CEO. His key equity portfolio investments such as Apple, American Express, and Coca-Cola have done well by way of capital appreciation, while also fetching him dividend income.

Ramaswamy, the founder of Roivant Sciences Ltd. (NASDAQ:ROIV), a biopharma portfolio company, once aspired to make it the “Berkshire Hathaway” of drug development, the report said, citing Forbes.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Roivant bought an Alzheimer's candidate from GlaxoSmithKline (NYSE:GSK) for $5 million in 2015 and then shelved the drug after it flopped in clinical trials.

The company began adding portfolio companies and in 2019, it agreed to sell five of its subsidiaries to Japan’s Sumitomo Dainippon Pharma for $3 billion. The Japanese company also took a 10% stake in Roivant.

Corporate Social Agenda: Buffett, though not anti-climate, is not in favor of “social governance warriors seeking to hijack corporate mission,” a New York Times report said. “To Mr. Buffett, boards' rightful role is, as ever, to serve the shareholders who have risked their capital,” it added.

This starkly contrasts the stances of several so-called progressive institutional investors, which have pushed for environmental, social, and governance investing. Additionally, companies have adopted climate and diversity policies.

Ramaswamy, a self-proclaimed “anti-woke crusader” has been critical of companies and investment managers not performing their fiduciary duties by pursuing social agendas.

In a 2022 post on the Harvard Law School Forum, Ramaswamy said, “Under the sole interest rule, asset managers cannot be influenced by their own interests, by the interests of third-party ‘stakeholders,' by ‘social' objectives, or by any motives other than what's best for their clients.

He also cried foul over BlackRock calling for U.S. oil companies to reduce oil production to fight climate change but being a shareholder in foreign oil companies such as PetroChina. The firm also drew flake recently for naming Saudi Aramco Chairman and CEO Amin Nasser to its board.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Read Next: Vivek Ramaswamy’s ‘Shady’ Use Of Eminem’s Rap Draws Rebuke — From Marshall Mathers Himself

Photos via Shutterstock

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.